> Eli Lilly said Monday it will not raise its buyout price for biotechnology company SGX Pharmaceutical, describing its bid of $3-per-share bid as its "best and final offer." Report
> GlaxoSmithKline laid off 22 more employees at its North Carolina research facility following an earlier summer dismissal of 100 scientific workers. Report
> Bayer filed a patent infringement lawsuit to prevent Novartis' generic drugs unit Sandoz from selling a copycat version of the German group's oral contraceptive YAZ in the United States. Report
> Boehringer Ingelheim said its Aptivus AIDS drug was shown to be effective and safe for children and adolescents in a two-year study involving 78 patients who had previously received other treatments. Report
> Medicines Co. got FDA approval to market its injectable drug Cleviprex for patients with difficult-to-treat high blood pressure. Report
> Ranbaxy Laboratories said that the World Health Organization had included another of its HIV-fighting drugs on its prequalification list, bringing the number of its AIDS meds on that list to 18. Report
> A drug used to fight tuberculosis also hampers the effectiveness of an HIV treatment widely used in Africa, the world's worst AIDS-hit region, a new study said. Report
> Madison, WI-based OpGen, which has developed new technology to map a microorganism's genome, is moving to Montgomery County in Maryland and plans to swiftly ramp up operations with new hires. OpGen report
> The tiny, Portland-based developer Dimera tells the local Business Journal that the company needs to raise $40 million in order to survive. Dimera report
> Schering-Plough published promising new data for its experimental hepatitis C drug boceprevir, which pushed down the share value of rival Vertex Pharmaceuticals. Report
> The largely unknown TauRx has been basking in the limelight of some startling efficacy data for its experimental Alzheimer's drug--Rember. Now TauRx officials tell The Times that ongoing discussions may soon lead to new partnerships. Report
And Finally... Megadoses of vitamin C halved the size of tumors in mice, a new study shows. Report